The patient had received imatinib 400 mg daily in the first 8 years after CML diagnosis, with deep molecular remission (BCR::ABL/ABL 0.5% International Scale MR4, MR4,5), which had to be discontinued due to recurrent episodes of hemorrhagic eyelid edema and moderate anemia associated with the drug. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.